Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annexon, Inc. (Nasdaq: ANNX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory documents, including current reports, registration statements and other disclosures related to its complement-focused neuroinflammation platform. Annexon is a clinical-stage biopharmaceutical company developing C1q- and classical complement-targeted therapies for neuroinflammatory and complement-mediated diseases of the body, brain and eye.
Through this page, readers can review Annexon’s Form 8-K current reports, which have included announcements of quarterly financial results, portfolio progress and material changes affecting security holders, such as amendments to common stock purchase warrants. Filings related to public offerings of common stock and pre-funded warrants are made under an effective Form S-3 shelf registration statement, with prospectus supplements detailing the terms of each offering.
As Annexon advances late-stage programs such as tanruprubart in Guillain-Barré syndrome and vonaprument in geographic atrophy, investors may also monitor future annual reports on Form 10-K, quarterly reports on Form 10-Q and additional 8-K filings for updates on clinical development, cash runway and risk factors. Any insider transactions by officers and directors would be reported on Form 4 and can be reviewed alongside these company-level filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, explain technical language and help users quickly understand the implications of new filings. Real-time updates from EDGAR ensure that new Annexon filings appear promptly, while AI-generated overviews of 10-K, 10-Q and 8-K reports, as well as insider trading forms, support more efficient analysis of the company’s regulatory and financial disclosures.
Filing: Schedule 13G/A (Amendment No. 3) reporting beneficial ownership in Annexon Inc. (ANNX) as of 06/30/2025; signature dated 08/05/2025.
Key facts
- Reporting persons: FMR LLC and Abigail P. Johnson.
- Aggregate beneficial ownership: 15,695,226.36 shares, representing 14.3% of the class.
- Voting/dispositive powers reported: FMR LLC sole voting power 15,690,765.00; sole dispositive power 15,695,226.36; shared powers 0.00; Abigail P. Johnson reports sole dispositive power 15,695,226.36; no voting power.
Certification: Signatory certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 references included.
Annexon, Inc. (NASDAQ: ANNX) filed a Form 144 disclosing a proposed insider sale of up to 853 common shares, valued at approximately $2,226.42. The shares, representing roughly 0.0008% of the 109.7 million shares outstanding, were acquired through restricted-stock vesting on 07 Jul 2025 and are slated for sale on or about 14 Jul 2025 via Fidelity Brokerage Services LLC on the NASDAQ exchange.
No other sales by the filer in the past three months were reported, and the filing contains the standard affirmation that the seller possesses no undisclosed material adverse information. Filer name and relationship to the issuer were not provided, suggesting an administrative notice rather than a significant ownership change.
Given the minimal share count and dollar value, this transaction is considered routine and unlikely to affect Annexon’s capital structure, liquidity, or share price. Investors typically view such small-scale Form 144 filings as non-material disclosures.
Annexon, Inc. (ANNX) has filed a Form 144 indicating the planned sale of 1,117 common shares through Fidelity Brokerage Services on 14 July 2025. The shares, valued at an aggregate $2,880.97, were acquired via restricted-stock vesting on 11 July 2025 as compensation. Outstanding shares total 109,714,404; therefore, the proposed sale represents roughly 0.001% of shares outstanding, a de-minimis amount that will not affect float or control. No other sales have occurred in the past three months, and the filer affirms no undisclosed material adverse information.